GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Exact Sciences Corp (FRA:EXK) » Definitions » Cyclically Adjusted PS Ratio

Exact Sciences (FRA:EXK) Cyclically Adjusted PS Ratio : 6.22 (As of Jun. 02, 2025)


View and export this data going back to . Start your Free Trial

What is Exact Sciences Cyclically Adjusted PS Ratio?

As of today (2025-06-02), Exact Sciences's current share price is €50.47. Exact Sciences's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was €8.12. Exact Sciences's Cyclically Adjusted PS Ratio for today is 6.22.

The historical rank and industry rank for Exact Sciences's Cyclically Adjusted PS Ratio or its related term are showing as below:

FRA:EXK' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 4.71   Med: 48.39   Max: 273
Current: 6.37

During the past years, Exact Sciences's highest Cyclically Adjusted PS Ratio was 273.00. The lowest was 4.71. And the median was 48.39.

FRA:EXK's Cyclically Adjusted PS Ratio is ranked worse than
81.06% of 132 companies
in the Medical Diagnostics & Research industry
Industry Median: 2.065 vs FRA:EXK: 6.37

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Exact Sciences's adjusted revenue per share data for the three months ended in Mar. 2025 was €3.500. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €8.12 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Exact Sciences Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Exact Sciences's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Exact Sciences Cyclically Adjusted PS Ratio Chart

Exact Sciences Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 51.03 20.07 9.21 10.56 6.73

Exact Sciences Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.21 5.46 8.56 6.73 4.90

Competitive Comparison of Exact Sciences's Cyclically Adjusted PS Ratio

For the Diagnostics & Research subindustry, Exact Sciences's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Exact Sciences's Cyclically Adjusted PS Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Exact Sciences's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Exact Sciences's Cyclically Adjusted PS Ratio falls into.


;
;

Exact Sciences Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Exact Sciences's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=50.47/8.12
=6.22

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Exact Sciences's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Exact Sciences's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=3.5/134.9266*134.9266
=3.500

Current CPI (Mar. 2025) = 134.9266.

Exact Sciences Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 0.081 100.684 0.109
201509 0.119 100.392 0.160
201512 0.137 99.792 0.185
201603 0.137 100.470 0.184
201606 0.193 101.688 0.256
201609 0.239 101.861 0.317
201612 0.306 101.863 0.405
201703 0.409 102.862 0.536
201706 0.455 103.349 0.594
201709 0.511 104.136 0.662
201712 0.615 104.011 0.798
201803 0.605 105.290 0.775
201806 0.721 106.317 0.915
201809 0.826 106.507 1.046
201812 1.022 105.998 1.301
201903 1.136 107.251 1.429
201906 1.369 108.070 1.709
201909 1.533 108.329 1.909
201912 1.900 108.420 2.365
202003 2.125 108.902 2.633
202006 1.595 108.767 1.979
202009 2.309 109.815 2.837
202012 2.449 109.897 3.007
202103 1.993 111.754 2.406
202106 2.104 114.631 2.477
202109 2.256 115.734 2.630
202112 2.431 117.630 2.788
202203 2.533 121.301 2.818
202206 2.798 125.017 3.020
202209 2.985 125.227 3.216
202212 2.939 125.222 3.167
202303 3.151 127.348 3.339
202306 3.186 128.729 3.339
202309 3.198 129.860 3.323
202312 3.275 129.419 3.414
202403 3.216 131.776 3.293
202406 3.525 132.554 3.588
202409 3.455 133.029 3.504
202412 3.676 133.157 3.725
202503 3.500 134.927 3.500

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Exact Sciences  (FRA:EXK) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Exact Sciences Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Exact Sciences's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Exact Sciences Business Description

Traded in Other Exchanges
Address
5505 Endeavor Lane, Madison, WI, USA, 53719
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.